In Escherichia coli, expression of the multiple antibiotic resistance (MAR) phenotype is mediated by the decreased expression of the porin OmpF and overexpression of the acrAB locus encoding the multidrug efflux pump AcrB, controlled by the marRAB operon, although it may also involve other efflux systems yet to be identified (1) . MarA is a transcriptional activator for marRAB and binds to the marbox located within the operator marO. Homologues of MarA, such as SoxS and Rob, have been shown to bind to the marbox and also regulate expression of the mar locus (15, 24) . The expression of the E. coli AcrAB efflux system is increased in MAR mutants, and overexpression of acrAB confers organic-solvent tolerance as well as MAR (25, 32) . The outer membrane protein TolC, proposed to act as an efflux channel for AcrAB, is essential for the maintenance of organic-solvent tolerance. Like marRAB, acrAB and tolC are positively regulated by MarA, SoxS, and Rob (2, 7, 25, 32) .
Less is known about the control of MAR in salmonella. Studies have shown that some MAR mutants of salmonella have reduced expression of OmpF (14, 26, 27) , while other MAR isolates have no porin changes (10, 11, 26) . The marRAB locus in Salmonella enterica serovar Typhimurium has been shown to be structurally and functionally similar to that in E. coli (29) , and there is close homology between the soxRS genes of Salmonella serovar Typhimurium and E. coli (28) .
Lacroix et al. constructed an acrB-disrupted mutant of Salmonella serovar Typhimurium which lost the ability to grow in the presence of bile salts and chemical detergents and showed increased susceptibility to antibiotics (16, 17 ). An AcrAB-overproducing mutant of Salmonella serovar Typhimurium with reduced susceptibility to multiple antibiotics compared to its parent strain has also been described (22) . Recently, mutants of Salmonella serovar Typhimurium with reduced accumulation of ciprofloxacin have been shown to overexpress AcrA, suggesting the involvement of the AcrAB efflux pump in multiple drug resistance (11) .
The clinical isolates of Salmonella serovar Typhimurium used in the present study have been described previously (26, 27) . Strain L3 was isolated from a hematoma in a patient prior to intravenous ciprofloxacin therapy, and 11 quinolone-resistant posttherapy isolates were obtained from wound drainage fluid over a period of 19 weeks. Several of the posttherapy strains were subsequently shown to harbor mutations in gyrA (12, 26) or gyrB (9) . No mutations were detected in parC (unpublished data). Six posttherapy isolates were MAR and had reduced accumulation of ciprofloxacin and norfloxacin which did not correlate with lack of OmpF. In the present study, we sought to further characterize the mechanism of MAR and reduced accumulation in these isolates and to ascertain the role of efflux in the resistance phenotype.
MATERIALS AND METHODS
Bacterial strains and susceptibility to antibiotics, dyes, detergents, and organic solvents. Salmonella serovar Typhimurium L3 was isolated from a patient prior to a course of ciprofloxacin. Six posttherapy strains were MAR and exhibited reduced accumulation of quinolones, and in addition, L5 possessed a mutation in gyrA (Ala1193Glu) and L18 possessed a mutation in gyrB (Ser4633Tyr) which contributed to quinolone resistance (9, 12, 26, 27) . The remaining isolates had no mutations in gyrA or gyrB. Salmonella serovar Typhimurium NCTC 74 (L19) was obtained from the Public Health Laboratory Service (Colindale, United Kingdom), and Salmonella serovar Typhimurium T39 (parent strain; spontaneous streptomycin-resistant mutant) and LX1054 (acrB mutant) were supplied by F. Lacroix (16) . Susceptibility to antimicrobial agents, detergents, and dyes and tolerance to hexane and cyclohexane were determined as described previously (4, 13, 32) .
Antibiotic accumulation. The accumulation of ciprofloxacin, [ 3 H]chloramphenicol, and [ 3 H]tetracycline by all isolates, with and without the presence of 100 M carbonyl cyanide m-chlorophenylhydrazone (CCCP), was measured as described previously (5, 18) .
DNA isolation, PCR, and DNA sequencing. Genomic DNA was prepared using cetyltrimethylammonium bromide (CTAB)-chloroform extraction (6) . The marR and marO regions were amplified from genomic DNA using primers derived from the Salmonella serovar Typhimurium marRAB sequence (29) as described previously (12) . A 1,536-nucleotide acrB gene fragment was amplified using the primers derived from the partial sequence of Salmonella serovar Typhimurium LX1054 acrB (17) . Gene fragments of acrR and the putative promoter region of acrAB were amplified by PCR using primers derived from the sequences of E. coli acrRAB (20) . DNA sequencing was performed by MWGBiotech AG (Ebersberg, Germany).
Northern blot analysis for acrB, tolC, marA, and soxS. For Northern blot analysis of marA and soxS, total RNA was extracted with an RNeasy Midi kit (Qiagen). The probes for marA and soxS were prepared by PCR, [ 32 P]dCTP labeled with the High Prime DNA labeling kit (Boehringer Mannheim Corporation), and hybridized to the RNA in ULTRAhyb ultrasensitive hybridization solution (Ambion) according to the manufacturer's protocol. Northern blotting of acrB (1,067 nucleotides; analogous to nucleotides 3550 to 4616 of E. coli acrAB) and tolC was performed with RNA extracted with TRIZOL (Life Technologies Ltd.) and as described in the Gene Images kit (Amersham Pharmacia Biotech). Probes for acrB and tolC were prepared by PCR and labeled with fluorescein using the Gene Images kit. Sample-to-sample RNA uniformity was determined by examining 16S rRNA expression in parallel. DNA sequencing of all probes confirmed their identities.
QCRT-PCR of acrB. Differential expression of acrB mRNA was compared by quantitative competitive reverse transcription-PCR (QCRT-PCR) as described by Freeman et al. (8) . An 894-bp internal competitor DNA standard for acrB was generated by PCR amplification of genomic DNA using primer STACRB1 (CGAGAACGTCGAACGTGTTA) and the 40-mer reverse primer ACRBi (TC ACACGACCGCGATCGATAGCCGAACAACTGATTACGTG). Total RNA was extracted with TRIZOL reagent. Reverse transcriptase PCR was performed on the RNA template to generate cDNA of acrB. Competitor DNA was added at concentrations from 0.01 to 2 pg to replicate tubes containing identical aliquots of cDNA. PCR was performed on the competitor DNA-cDNA mixture using primers STACRB1 and ACRBR1 (TCACACGACCGCGATCGATA). The two products were separated by polyacrylamide gel electrophoresis, the gel was silver stained (31) , and the bands were quantified by densitometry. The concentration of competitor DNA at which both bands were of equal density was taken to be the concentration of the target cDNA.
SSCP analysis of acrR and the putative promoter region of acrAB. Genomic DNA was prepared using CTAB-chloroform extraction (6) , and acrR and the putative acrAB promoter region were amplified by PCR using three pairs of primers based on the acrRAB sequence from E. coli (20) . The PCR amplimers were analyzed by single-strand conformational polymorphism (SSCP) as described previously (31) .
Nucleotide sequence accession numbers. The DNA sequences from wild-type Salmonella serovar Typhimurium NCTC 74 were submitted to GenBank under accession numbers U78314 (acrB-like gene) and AF209869 to AF209870 (acrR and the putative promoter region of acrAB).
RESULTS AND DISCUSSION
All six posttherapy isolates were less susceptible to nalidixic acid, ciprofloxacin, and other antibiotics than the pretherapy isolate, L3. L6, L10, L12, and L15 were also more resistant to dyes and detergents (Table 1) . L5 was as susceptible to dyes and detergents as L3, while L18 was fourfold more resistant to acriflavine only (Table 1) . Isolates L6, L10, and L12 were hexane tolerant. For all strains, the MIC of ciprofloxacin was unaltered by the presence of 100 M CCCP, and none of the strains grew in the presence of cyclohexane.
Isolates L5, L6, L10, L12, and L15 accumulated approxi- mately two-to fourfold less ciprofloxacin than L3 (Table 2 ). In the presence of CCCP, the concentrations of ciprofloxacin accumulated by L5, L6, and L10 increased to that accumulated by L3. The concentration of ciprofloxacin accumulated by L15 was almost doubled in the presence of CCCP, but it remained less than half that observed in L3. CCCP had no effect upon ciprofloxacin accumulation for isolates L12 and L18. L6, L12, and L15 accumulated approximately three-quarters and L10 accumulated one-third the concentration of chloramphenicol accumulated by L3. The concentrations of chloramphenicol accumulated by all isolates except L12 were increased in the presence of CCCP ( Table 2 ). All six posttherapy isolates accumulated approximately two-to fourfold less tetracycline than L3 (Table 2 ). In the presence of CCCP, the accumulation of tetracycline by L5, L6, L15, and L18 was increased to concentrations similar to that accumulated by L3. Although the concentrations of tetracycline accumulated by L10 and L12 approximately doubled in the presence of CCCP, they still remained less than half that of L3. Northern blot analysis indicated that none of the clinical strains overexpressed marA, soxS, or tolC; tolC was expressed at low levels. The posttherapy isolates L5, L10, and L18 showed consistently higher transcript levels of acrB than the pretherapy isolate, L3 (Fig. 1) . No acrB transcripts were detected in the acrB mutant LX1054. QCRT-PCR demonstrated that L10 expressed four times and L5 and L18 expressed two and a half times more acrB mRNA than L3. SSCP analysis of the entire acrR gene and the putative promoter region of acrAB identified mutations within these regions in control strains of E. coli (data not shown); however, all posttherapy isolates of Salmonella serovar Typhimurium showed patterns identical to those of the pretherapy isolate, L3, and the control, L19. The SSCP data were corroborated by DNA sequencing, which confirmed that there were no mutations within the region.
Recent work has suggested that the AcrAB efflux pump of E. coli plays a major role in MAR, as fluoroquinolone resistance was lost on inactivation of the acrAB locus in strains with mutations in gyrA (23) . The same may not be true for salmonella, as CCCP (which should inactivate AcrB) made no difference in susceptibility to ciprofloxacin for any of the isolates in the present study, including both isolates with gyrase mutations (L5 gyrA and L18 gyrB; data not shown).
To confirm that MAR in the isolates L5, L10, and L18 is mediated by AcrB efflux, we propose to inactivate acrB in these strains and examine whether the phenotype is reversed by disruption of the gene. This work is currently under way. It is unlikely that sequencing of the acrAB gene cluster in these isolates would reveal any mutations, as changes in this gene have been shown to increase susceptibility in Salmonella serovar Typhimurium (17, 22) . As SSCP analysis and DNA sequencing of acrR and the promoter region of acrAB failed to show any differences between the MAR isolates and the pretherapy parent strain, any mutation mediating resistance is more likely to be found in a regulatory gene. The data presented here also suggest that marOR, soxS, and tolC are not overexpressed. However, in E. coli, TolC has been shown to be essential for the function of the AcrB efflux pump (7) and for the maintenance of organic-solvent tolerance (2) . It may be that the low level of TolC was sufficient to act as an outer membrane channel for AcrAB; however, an alternative explanation for the data is that another pump which affects the expression of acrB may be involved in multiple antibiotic resistance in Salmonella serovar Typhimurium and may explain the apparent lack of involvement of TolC in the resistance phenotype of these isolates. Only three of the six strains in the present study exhibited any degree of organic-solvent tolerance (L6, L10, and L12 to hexane only), which may be consistent with the lack of increased expression of tolC in these isolates. It would be interesting to examine whether the expression of Rob is increased in these isolates, as it is known that this protein affects the function of the AcrAB efflux pump in E. coli (3, 30) . Unfortunately, despite employing a variety of strategies, PCR amplification of rob using primers based on the DNA sequence of E. coli rob failed to amplify its homologue from chromosomal or plasmid DNA preparations from any of the control or clinical isolates of Salmonella serovar Typhimurium (unpublished data).
The accumulation of ciprofloxacin by L15 and tetracycline by L12 was increased by CCCP but remained well below the concentrations accumulated by L3. Similarly, reduced accumulation of ciprofloxacin and chloramphenicol by L12 was unaffected by CCCP. This suggests that accumulation was reduced in these two strains by an additional mechanism resistant to CCCP inhibition. Previous work has shown that reduced outer membrane permeability did not contribute to resistance in L12 and L15 (26) . It is probable that another efflux pump with a substrate profile similar to that of AcrB but which is resistant to inhibition by CCCP, perhaps similar to EmrAB of E. coli, is contributing to resistance in L12 and L15 (21) . The use of other efflux inhibitors may help elucidate the nature of other putative efflux pumps in salmonella. It is evident that isolates with quite different phenotypes arose in this patient, and it is likely that individual isolates may possess a complex mixture of multiple mutations.
The regulation of AcrB-mediated efflux in Salmonella serovar Typhimurium remains to be established and may differ from that described for E. coli (1). Ma et al. (19) found increased transcription of acrAB in E. coli strains which lacked acrR when exposed to general stress conditions. They concluded that acrR is a secondary modulator of acrRAB expression and suggested that up-regulation under general stress conditions is controlled by an unidentified regulator, possibly a homologue of the known global regulator MarA, SoxS, or Rob. It is feasible that this alternative regulatory mechanism, independent of mar-sox-rob, may be responsible for the control of AcrB expression in Salmonella serovar Typhimurium, and this requires further investigation. When the sequencing of the Salmonella serovar Typhimurium LT2 genome is completed FIG. 1 . Northern blot analysis of acrB transcript levels in clinical isolates of Salmonella serovar Typhimurium, Salmonella serovar Typhimurium L19 (NCTC 74), and strains T39 (wild type) and LX1054 (T39 carrying a TnphoA insert disrupting acrB [17] ). (33) , identification of homologues of the known regulators of the mar regulon of E. coli will help to elucidate the regulation of efflux-mediated fluoroquinolone resistance in Salmonella serovar Typhimurium.
